• Cat-intel
  • MedIntelliX
  • Resources
  • About Us
  • Request Free Sample ×

    Kindly complete the form below to receive a free sample of this Report

    Leading companies partner with us for data-driven Insights

    clients tt-cursor

    Diabetic Lancing Device Market

    ID: MRFR/MED/4060-HCR
    90 Pages
    Kinjoll Dey
    September 2025

    Diabetic Lancing Device Market Research Report By type (push button safety lancets, pressure activated safety lancets, side button safety lancets), by gauge (17/18g, 21g, 23g, 25g, 28g,& 30g), by penetration depth, by end-user-forecast till 2032

    Share:
    Download PDF ×

    We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

    Diabetic Lancing Device Market Research Report- Forecast To 2032 Infographic
    Purchase Options
    $ 4,950.0
    $ 5,950.0
    $ 7,250.0

    Diabetic Lancing Device Market Summary

    The Global Diabetic Lancing Device Market is projected to grow from 1.6 USD Billion in 2024 to 3.18 USD Billion by 2035.

    Key Market Trends & Highlights

    Diabetic Lancing Device Key Trends and Highlights

    • The market is expected to experience a compound annual growth rate (CAGR) of 6.43% from 2025 to 2035.
    • By 2035, the market valuation is anticipated to reach 3.18 USD Billion, indicating robust growth.
    • In 2024, the market is valued at 1.6 USD Billion, reflecting a strong foundation for future expansion.
    • Growing adoption of advanced diabetic management technologies due to increasing prevalence of diabetes is a major market driver.

    Market Size & Forecast

    2024 Market Size 1.6 (USD Billion)
    2035 Market Size 3.18 (USD Billion)
    CAGR (2025-2035) 6.43%

    Major Players

    B. Braun Melsungen AG, Terumo Corporation, Becton Dickinson, Sanofi, F. Hoffmann-La Roche AG, Bayer AG, Novo Nordisk A/S, Eli Lilly and Company, Owen Mumford Ltd, Medtronic, Ypsomed Holding AG, Sarstedt AG & Co, Greiner Bio One, Abbott Laboratories, HTL-STREFA S.A, Improve Medical, UltiMed, Inc., Allison Medical, Inc., Artsana S.p.a., VOGT MEDICAL, Perrigo Diabetes Care, MedExel Co. Ltd, ARKRAY Inc., Simple Diagnostics, Stat Medical, Terumo, Trividia Health

    Diabetic Lancing Device Market Drivers

    Market Growth Projections

    The Global Diabetic Lancing Device Market Industry is projected to experience substantial growth, with estimates indicating a market value of 1.6 USD Billion in 2024 and a potential increase to 3.18 USD Billion by 2035. This growth trajectory suggests a compound annual growth rate of 6.43% from 2025 to 2035. Such projections highlight the increasing demand for diabetic lancing devices driven by factors such as rising diabetes prevalence, technological advancements, and supportive healthcare policies. The market's expansion reflects a broader trend towards improved diabetes management solutions on a global scale.

    Technological Advancements

    Technological innovations in diabetic lancing devices significantly influence the Global Diabetic Lancing Device Market Industry. Recent developments include devices that minimize pain and enhance user experience, such as those with adjustable depth settings and advanced safety features. These advancements not only improve patient compliance but also attract new users. As a result, the market is expected to grow at a compound annual growth rate of 6.43% from 2025 to 2035, reaching an estimated value of 3.18 USD Billion by 2035. Such innovations are crucial in addressing the diverse needs of diabetic patients.

    Increasing Health Awareness

    Growing awareness regarding diabetes management and the importance of regular blood glucose monitoring is driving the Global Diabetic Lancing Device Market Industry. Educational campaigns by health organizations and governments emphasize the significance of early detection and continuous monitoring. This heightened awareness leads to increased adoption of lancing devices among patients, healthcare providers, and caregivers. As a result, the market is witnessing a steady rise in demand, contributing to its projected growth trajectory. The emphasis on preventive healthcare is likely to further bolster the market's expansion in the coming years.

    Rising Geriatric Population

    The global increase in the geriatric population is a significant factor influencing the Global Diabetic Lancing Device Market Industry. Older adults are more susceptible to diabetes and often require regular monitoring to manage their condition effectively. According to the United Nations, the number of individuals aged 60 years and older is expected to reach 2.1 billion by 2050. This demographic shift necessitates the development of user-friendly lancing devices tailored to the elderly, thereby driving market growth. The demand for devices that cater to this population segment is likely to increase as the aging population continues to expand.

    Rising Prevalence of Diabetes

    The increasing incidence of diabetes globally serves as a primary driver for the Global Diabetic Lancing Device Market Industry. According to the World Health Organization, the number of adults living with diabetes is projected to rise from 422 million in 2014 to an estimated 642 million by 2040. This alarming trend necessitates effective blood glucose monitoring solutions, thereby propelling demand for lancing devices. In 2024, the market is valued at approximately 1.6 USD Billion, reflecting the urgent need for innovative and user-friendly devices to manage diabetes effectively.

    Regulatory Support and Reimbursement Policies

    Supportive regulatory frameworks and favorable reimbursement policies play a crucial role in shaping the Global Diabetic Lancing Device Market Industry. Governments and health authorities are increasingly recognizing the importance of diabetes management, leading to the establishment of policies that facilitate access to essential medical devices. Reimbursement for lancing devices encourages patients to utilize these tools, thereby enhancing market penetration. As healthcare systems evolve to prioritize chronic disease management, the positive impact of these policies on market growth is expected to become more pronounced in the coming years.

    Key Companies in the Diabetic Lancing Device Market market include

    Future Outlook

    Diabetic Lancing Device Market Future Outlook

    The Global Diabetic Lancing Device Market is projected to grow at a 6.43% CAGR from 2024 to 2035, driven by technological advancements, increasing diabetes prevalence, and rising awareness of self-monitoring.

    New opportunities lie in:

    • Develop smart lancing devices integrated with mobile health applications for real-time data tracking.
    • Expand product lines to include eco-friendly, sustainable materials appealing to environmentally conscious consumers.
    • Leverage telehealth partnerships to enhance remote patient monitoring and device accessibility.

    By 2035, the market is expected to achieve robust growth, solidifying its position as a key player in diabetes management.

    Market Segmentation

    Diabetic Lancing Device Market Segmentation

    Diabetic Lancing Device Market Key Players
    • B. Braun Melsungen AG
    • Terumo Corporation
    • Becton Dickinson
    • Sanofi
    • F. Hoffmann-La Roche AG
    • Bayer AG, Novo Nordisk A S
    • Eli Lilly and Company
    • Owen Mumford Ltd
    • Medtronic
    • Ypsomed Holding AG
    • Sarstedt AG & Co
    • Greiner Bio One
    • Abbott Laboratories
    • HTL-STREFA S.A, Improve Medical
    • UltiMed, Inc.
    • , Inc.
    • Artsana S.p.a.
    • VOGT MEDICAL
    • Perrigo Diabetes Care
    • MedExel Co. Ltd
    • ARKRAY Inc.
    • Simple Diagnostics
    • Stat Medical
    • Terumo
    • Trividia Health

    Report Scope

    Report Attribute/Metric Details
    Market Size 2023 1.5 (USD Billion)
    Market Size 2024 1.6 (USD Billion)
    Market Size 2032 2.1 (USD Billion)
    Compound Annual Growth Rate (CAGR) 14.8 % (2024 - 2032)
    Report Coverage Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
    Base Year 2023
    Market Forecast Period 2024 - 2032
    Historical Data 2019 - 2023
    Forecast Units Value (USD Billion)
    Segments Covered Type, Application, and End-User
    Geographies Covered North America, Europe, Asia-Pacific, and Rest of the World (RoW)
    Key Vendors B. Braun Melsungen AG, Terumo Corporation, Becton Dickinson, Sanofi, F. Hoffmann-La Roche AG, Bayer AG, Novo Nordisk A/S, Eli Lilly and Company, Owen Mumford Ltd, Medtronic, Ypsomed Holding AG, Sarstedt AG & Co, Greiner Bio One, Abbott Laboratories, HTL-STREFA S.A, Improve Medical, UltiMed, Inc., Allison Medical, Inc., Artsana S.p.a., VOGT MEDICAL, Perrigo Diabetes Care, MedExel Co. Ltd, ARKRAY Inc., Simple Diagnostics, Stat Medical, Terumo, Trividia Health
    Key Market Opportunities Rising prevalence of diabetes, increasing awareness of blood glucose monitoring devices, government support, and rising investments in healthcare
    Key Market Drivers Growing demand for diabetic lancing devices due to increasing diabetic population, awareness of safety measures, and technological advancements

    Market Highlights

    Author
    Kinjoll Dey
    Research Analyst Level I

    He is an extremely curious individual currently working in Healthcare and Medical Devices Domain. Kinjoll is comfortably versed in data centric research backed by healthcare educational background. He leverages extensive data mining and analytics tools such as Primary and Secondary Research, Statistical Analysis, Machine Learning, Data Modelling. His key role also involves Technical Sales Support, Client Interaction and Project management within the Healthcare team. Lastly, he showcases extensive affinity towards learning new skills and remain fascinated in implementing them.

    Leave a Comment

    FAQs

    At what CAGR is the global diabetic lancing device market projected to grow in the forecast period (2024-2032)?

    diabetic lancing device market is projected to grow at approximately 14.80% CAGR during the assessment period (2024-2032).

    What are the major tailwinds pushing the growth of the global diabetic lancing device market?

    Features of these devices such as painless vein puncture, easy handling, and safety, rising prevalence of diabetic population, and increasing awareness for blood glucose monitoring device, are major tailwinds pushing the growth of the global diabetic lancing device market.

    What are the key growth impeders of the global diabetic lancing device market?

    High price and significant changes in reimbursement policies blood glucose monitors, are major growth impeder for the global diabetic lancing device market.

    Which region holds the largest share in the global diabetic lancing device market?

    Europe holds the largest share in the global diabetic lancing device market, followed by North America and the Asia Pacific, respectively.

    Who are the top players in the global diabetic lancing device market?

    B. Braun Melsungen AG, Becton Dickinson, Terumo Corporation, Sanofi, F. Hoffmann-La Roche AG, Novo Nordisk A S, Bayer AG, Eli Lilly and Company, Medtronic, Owen Mumford Ltd, Ypsomed Holding AG, Greiner Bio One, Sarstedt AG & Co, Abbott Laboratories, Improve Medical, HTL-STREFA S.A, UltiMed, Inc., Artsana S.p.a., Allison Medical, Inc., VOGT MEDICAL, MedExel Co., Ltd, Perrigo Diabetes Care, ARKRAY Inc., Stat Medical, Simple Diagnostics, Terumo, and Trividia Health, are some of the top players operating in the global diabetic lancing device market.

    Diabetic Lancing Device Market Research Report- Forecast To 2032 Infographic
    Free Sample Request

    Kindly complete the form below to receive a free sample of this Report

    Customer Strories

    “I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

    Victoria Milne Founder
    Case Study

    Chemicals and Materials